---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-197124"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:36:52.910373+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M

## Summary
- Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.
- Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).
- Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.
- FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.
- Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-197124
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/0001193125-26-197124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-197124
- JSON: https://secwatch.observer/filing/0001193125-26-197124.json
- Plain text: https://secwatch.observer/filing/0001193125-26-197124.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $64.9 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total revenue of $64.9 million
  - Result: reported results
  source text: Syndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/0001193125-26-197124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.